Business
Ichnos Glenmark Innovation (IGI) and AbbVie Announce Exclusive Global Licensing Agreement for ISB 2001, a First-in-Class CD38×BCMA×CD3 Trispecific Antibody
IGI Therapeutics SA, a wholly owned subsidiary of New York-based Ichnos Glenmark Innovation, Inc. (IGI), and AbbVie (NYSE: ABBV) today announced an exclusive licensing agreement for IGI's lead investigational asset, ISB 2001, developed using IGI's proprietary BEAT® protein platform, for oncology and autoimmune diseases.
About this update from Abbvie Inc.
[{"type":"list","items":[{"val":[{"type":"text","content":"ISB 2001 is currently in Phase 1 clinical trial in patients with relapsed/refractory multiple myeloma (R/R MM)","length":115,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":115,"olType":false},{"type":"text","content":"NEW YORK and NORTH CHICAGO, Ill., July 10, 2025 /PRNewswire/ -- IGI Therapeutics SA, a wholly owned subsidiary of New York-based Ichnos Glenmark Innovation, Inc. (IGI), and AbbVie (NYSE: ABBV) today announced an exclusive licensing agreement for IGI's lead investigational asset, ISB 2001, developed using IGI's proprietary BEAT® protein platform, for oncology and autoimmune diseases.","length":403,"tagName":"p"},{"type":"image","alt":"IGI Logo (PRNewsfoto/Ichnos Glenmark Innovation)","displaySize":"","headline":null,"caption":"IGI Logo (PRNewsfoto/Ichnos Glenmark Innovation)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":78,"url":"https://media.zenfs.com/en/prnewswire.com/4cff5247748915a59542f22b96cc65f2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/MWMeCFp8agKJKvYVel_UAQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTEzNztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/4cff5247748915a59542f22b96cc65f2","width":400,"height":78}},"href":"https://mma.prnewswire.com/media/2728787/5409501/IGI_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":""Multispecifics including trispecific antibodies represent a bold new frontier in immuno-oncology with the potential to deliver deeper, more durable responses by engaging multiple targets simultaneously," said Roopal Thakkar, M.D., Executive Vice-President, Research and Development and Chief Scientific Officer, AbbVie. "This partnership with IGI reflects our unwavering commitment to advancing novel therapies for patients with multiple myeloma, a disease where significant unmet need remains despite recent progress."","length":540,"tagName":"p"},{"type":"text","content":""ISB 2001 exemplifies the potential of our BEAT® protein platform to generate effective multispecificsTM that may overcome resistance and improve outcomes in hard-to-treat cancers," said Cyril Konto, M.D., President and CEO of IGI. "This agreement marks a defining milestone in IGI's scientific journey and reflects our team's deep...